



## The Neurotoxicity of Biomedicines

Guest Editor:

### Dr. Wayne Carter

Clinical Toxicology, School of  
Medicine, The University of  
Nottingham, Nottingham NG7  
2RD, UK

Deadline for manuscript  
submissions:

**closed (31 January 2024)**

### Message from the Guest Editor

Neurotoxicity arises when excessive exposure to natural or synthetic substances detrimentally affects the functioning of the peripheral and/or central nervous system. Biomedicines or ethnomedicines may be neurotoxic by a number of molecular mechanisms, for example, via the induction of redox stress, and may trigger or contribute to neurodegeneration and neuronal death. In this Special Issue entitled 'The Neurotoxicity of Biomedicines' we are requesting manuscripts or review articles that cover agents that initiate or propagate neurotoxicity. This includes the neurotoxicity of biomedicines and ethnomedicines as pure or partially pure extracts or fractions, and the neurotoxicity of synthetic medicines. The evaluation of neurotoxicity will consider agent application to cell lines or administration to animals, or the neurotoxicity of an agent evidenced from human studies. The collation of novel research studies and review articles covering neurotoxicity will produce a useful resource of cutting-edge research in this field to help evaluate the next generation of biomedicines.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)